261633-71-0

Basic information

• Product Name: 2,3-DIHYDRO-1,4-BENZODIOXIN-5-YLMETHYLAMINE HYDROCHLORIDE
• Synonyms: 2,3-DIHYDRO-1,4-BENZODIOXIN-5-YLMETHYLAMINE HYDROCHLORIDE;2,3-Dihydro-1,4-benzodioxin-5-ylmethylamineHCl;2,3-Dihydro-1,4-benzodioxine-5-ylmethylamine;(2,3-dihydrobenzo[b][1,4]dioxin-5-yl)methanamine;2,3-dihydro-1,4-benzodioxin-5-MethanaMine;N-Methyl-2,3-dihydrobenzo[b][1,4]dioxin-5-aMine;2-amino-N-cyclopropyl-N-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)acetamide
• CAS NO: 261633-71-0
• Molecular Formula: C9H12ClNO2
• Molecular Weight: 201.65
• Mol File: 261633-71-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 287.5 °C at 760 mmHg
• Flash Point: 138.8 °C
• Appearance: /
• Density: 1.194 g/cm³
• Vapor Pressure: 0.00247mmHg at 25°C
• CAS DataBase Reference: 2,3-DIHYDRO-1,4-BENZODIOXIN-5-YLMETHYLAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-1,4-BENZODIOXIN-5-YLMETHYLAMINE HYDROCHLORIDE(261633-71-0)
• EPA Substance Registry System: 2,3-DIHYDRO-1,4-BENZODIOXIN-5-YLMETHYLAMINE HYDROCHLORIDE(261633-71-0)

Safety Data

• Hazard Codes: C:Corrosive
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 261633-71-0(Hazardous Substances Data)

Usage

Uses

2,3-Dihydro-1,4-benzodioxin-5-ylmethylamine, HCl

InChI:InChI=1/C9H11NO2.ClH/c10-6-7-2-1-3-8-9(7)12-5-4-11-8;/h1-3H,4-6,10H2;1H

Upstream product

• 214894-98-1 2-(2,3-dihydro-benzo[1,4]dioxin-5-ylmethyl)-isoindole-1,3-dione 
• 33632-34-7 5-methyl-2,3-dihydrobenzo[b][1,4]dioxine 
• 488-17-5 3-methylbenzene-1,2-diol 
• 214894-89-0 5-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine 

Downstream Products

• 1051929-86-2 tert-butyl 2-((tert-butoxycarbonyl)(methyl)amino)ethyl(3-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl-methyl)carbamoyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)carbamate 

Relevant articles and documents

Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus

This invention provides compounds of formula (IIA) and pharmaceutical compositions thereof, where M, a, b, and R1-R5 are as defined herein, for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes. Pharmaceutical compositions comprising the compounds of formula (IIA) are also disclosed.